Vericel shared its Q3 results, showing record sales over $85 million, up 26% from last year.

Nov 5, 2026, 9:43 AM ETResultsRead the original at Benzinga

Good for VCEL

Vericel’s third-quarter sales rose 26% to more than $85 million, and its full-year sales forecast increased to $344–$346 million. Profit also rose, despite continued spending to expand its sales team and commercial efforts, pointing to a stronger outlook.

VCEL · Vericel Corporation

AI read · Good for VCEL

The AI's read

Both main parts of the business contributed to the gains. MACI sales grew 21%, and Burn Care sales rose 52%; MACI also had record biopsies and implants. Profit climbed, too. Vericel is still expanding its sales team and commercial efforts, which means it continues to spend to support growth. The call reports stronger sales and profit alongside those investments.

Get alerts for VCEL

Follow Vericel Corporation (VCEL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VCEL

Free on the App Store and Google Play, or on the web.